35-year-old presents with suspected iris melanoma
A 35-year-old presented at Cole Eye Institute with a lesion in the left iris. He had been seen annually by an outside optometrist for seven years. The lesion had not been noted previously.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The patient did not have any visual symptoms, and his visual acuity was 20/20 in both eyes.
The elevated pigmented lesion in the iris was associated with nodularity along the pupillary margin between the 10- and 11-o’clock position. There were no feeder vessels or neovascularization of the iris on exam.
Anterior segment OCT showed multinodular iris thickening.
Although the lesion was small and appeared like a nevus, melanoma was suspected due to recent onset.
“Freckles and nevi of the iris are very common,” says Arun D. Singh, MD, Director of Ophthalmic Oncology at Cole Eye Institute. “All spots aren’t malignant, but there are some clues that can indicate which spots likely are.”
According to Dr. Singh, iris lesions suspicious for melanoma are those that:
Following discussion of treatment options, the patient agreed to undergo excisional biopsy of the lesion with pupilloplasty using a small-incision approach.
Conventionally, iris resection for a suspected malignancy has involved a large incision in the cornea and sclera and the removal of 25% or more of the iris. This sector iridectomy has been associated with increased risk of wound-related complications, tumor seeding and recurrence, and photophobia due to iris defect.
Almost 15 years ago, Dr. Singh developed a new technique: small-incision guarded hydroaspiration (SINGH procedure). Instead of one large incision, there are multiple small incisions. After excising the tumor, plastic tubing containing a sodium hyaluronate solution is inserted into the anterior chamber. Using a syringe, the excised lesion is pulled into the tube, where it is isolated and removed safely as the tube is withdrawn from the anterior chamber. This prevents the tumor from being pulled across the wound, possibly shedding cells and seeding the edges of the wound.
The next step, pupilloplasty, restores the iris to a near-normal shape with a suturing slip-knot technique since the iris does not have capacity to heal. This restoration of the iris not only repairs the cosmetic defect but helps prevent photophobia.
“Healing was much slower — six weeks or longer — with conventional techniques using the larger incision,” says Dr. Singh. “Distortion of the cornea was a problem too. If you’d make a 6 mm wound in the cornea, it would be irregular when it healed. Multiple smaller incisions allow faster healing. Patients typically have normal vision within a week or so.”
In this case, as clinically suspected, histopathology confirmed iris melanoma. All surgical margins were negative.
One day later, the patient’s vision was 20/30 with minimal postoperative inflammation.
Four weeks following surgery, the patient’s vision was normal (20/20) without change in corneal astigmatism. The pupil size was equal between the two eyes in ambient light.
Now three years since surgery, the patient remains recurrence-free.
Melanoma of the uvea is rare, occurring in just six per 1 million people. Approximately 10% of uveal melanoma occurs in the iris — extremely rare.
Two decades ago, the only option for removing uveal melanoma was an iridectomy with a large corneoscleral incision, requiring six weeks or more of healing and slow visual recovery. New techniques and better instrumentation now provide another option, with a better risk-benefit ratio, says Dr. Singh.
“Today, if I see a lesion growing, I recommend we remove it because I know we can do so safely with minimally invasive techniques,” he says. “In the past, we would just watch the lesion and hope to avoid a big surgery.”
Even small lesions can be suspicious for melanoma, which can be removed easily with low risk to the patient, he concludes.
An underdiagnosed condition in patients with cancer
Study demonstrates superior visualization of occult primary lesions
New device offers greater tumor control for malignant liver lesions
Cleveland Clinic researchers discover what drives – and what may halt – virus-induced cancer
First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention
New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients